Azura Ophthalmics News
9 articlesAzura Ophthalmics Expands Broad Intellectual Property Portfolio to 12 U.S. and European Patents
Azura Ophthalmics Provides Update on AZR-MD-001 Phase 2 Clinical Program Targeting Meibomian Gland Dysfunction
Azura Ophthalmics Announces Formation of Scientific Advisory Board (SAB)
Azura Ophthalmics Secures Grant to Evaluate AZR-MD-001 for Improved Vision Quality Related to Contact Lens Discomfort
growth-positive
Azura Ophthalmics Announces Positive Topline Results From Phase 2 Program of the Company's Investigational Treatment for Meibomian Gland Dysfunction
Azura Ophthalmics Ltd. has announced positive results from a phase 2 program evaluating its investigational therapy for Meibomian gland dysfunction (MGD). The therapy, AZR-MD-001, met its primary endpoints showing improvements in signs and symptoms of MGD. MGD is a chronic condition where the glands that line the eyelids become blocked, preventing them from secreting enough oil into the tear film needed to properly lubricate the eye. It is the main cause of Dry Eye Disease (DED). Azuras therapy is designed to restore Meibomian gland function by addressing the abnormal hyperkeratinization that blocks the glands.
Investment
Azura Ophthalmics Announces Primary Endpoints Met in Topline Results from Phase 2 Trial of the Company's Investigational Treatment for Contact Lens Discomfort
growth-positive
Eyeing pandemic's silver lining for drug trials
Azura Ophthalmics, a biotechnology company, has raised $28 million in funding for its ointment to prevent dry eye. The company, which has raised a total of $53 million, is focused on developing a compound to address Meibomian gland dysfunction, a cause of dry eye. The compound uses the active ingredient selenium disulfide, which is found in anti-dandruff shampoo Selsun Blue. Azura has created a safe method for applying the compound to the eyelids. The company aims to file for approval with the US Food and Drug Administration by the end of 2023. The recent funding round demonstrates confidence in the data from the companys tests.
Investment
growth-positive
Azura Ophthalmics gets a $20M boost for its R&D work on eye diseases
Azura Ophthalmics, a biotech company based in Tel Aviv-Yafo, Israel, has raised $20 million in funding from a group of investors. This brings their total fundraising amount to $38 million. The funding will support a registration study of their lead candidate, AZR-MD-001, which is designed to address Meibomian gland dysfunction and related eye diseases, including dry eye disease.
Investment
Azura Ophthalmics Receives $16 Million in Series B Funding to Develop Treatment for Leading Cause of Dry Eye Disease
